Mission statement

ALHI will bring together Australia’s leading researchers in respiratory health, along with cutting-edge engineering, data science and manufacturing, to help unlock the full disruptive potential of the revolutionary XV Technology™.  We are extremely excited about the opportunity to redefine how lung diseases are diagnosed and treated all over the world. The resulting successful commercialisation of two generations of scanners will be a major breakthrough in pulmonary health care, establishing Australia as a world leader in lung healthcare technology.

Success in this project will make a very big difference to the lives of children and adults suffering from lung disease in Australia and around the world.
Mark Brooke
Chief Executive Officer
Lung Foundation Australia

Latest from Twitter

Some patients discharged after COVID-19 infection show signs of restricted lung function. Ongoing monitoring of these patients will hopefully help with understanding pathophysiology of this disease. https://www.europeanlung.org/en/covid-19/covid-19-newsroom/recovering-from-covid-19

The metrics of respiratory disease in Australia: while not the highest cause of mortality, COPD (#3) and Asthma (#10) collectively have a higher overall burden (DALY) on our health system than our #1 killer - heart disease! https://bit.ly/2X8qMLy

The imaging hardware being developed by ALHI partners together with FDA approved XV technology from @4DMedicalXV Medical will for the first time provide a way to accurately quantitate and localise the extent of lung disease. Rapid, affordable and safe imaging for all patients!

4DMedical (formerly 4Dx)@4DMedicalXV

We're now FDA approved! https://www.prnewswire.com/news-releases/4dmedicals-lung-imaging-technology-receives-fda-clearance-as-covid-19-intensifies-global-focus-on-respiratory-health-301064672.html

Load More...